RxDoctor Payments Data

Siddharth Shah, MD

Neurology · New Port Richey, FLNPI 1174510358

Payments from drug & device makers

$32,075in general payments, 2019–2025

Across 422 payments — averaging $76.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$17K
  • Teva Pharmaceuticals USA, Inc.$9K
  • Biogen$2K
  • UCB, Inc.$611
  • Johnson & Johnson$486
  • Sunovion Pharmaceuticals Inc.$406
  • plus $3K from 37 others

What the payments were for

  • Consulting fees$3,75012%
  • Speaking & faculty fees$20,51464%
  • Travel & lodging$4801%
  • Food & beverage$7,20722%
  • Education$1240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,075 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$251,654
Medicare patients
399
Services billed
3,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b14$137,230
Rivastigmine19$3,608
Oxcarbazepine24$2,093
Carbidopa-LevodopaCarbidopa/Levodopa49$1,787
Levetiracetam58$1,683
Primidone50$1,187
Memantine Hcl27$1,145
Zonisamide16$1,075
Gabapentin30$498
Pregabalin14$426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerBetaseron$106$137,23014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in New Port Richey

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →